Minimal Effects of Cariprazine on Prolactin Levels in Bipolar Disorder and Schizophrenia

14Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Many medications used to treat schizophrenia and bipolar I disorder are linked to hyperprolactinemia. The effects of cariprazine, a dopamine D3 /D2 receptor partial agonist, on prolactin levels in patients with schizophrenia or bipolar I disorder were evaluated. Methods: Effects on prolactin were evaluated using pooled data from randomized, double-blind, placebo-controlled studies in patients with schizophrenia (4 studies; 6-week duration; cariprazine 1.5–3 mg/d, 4.5–6 mg/d, and 9–12 mg/d), bipolar mania (3 studies; 3-week duration; cariprazine 3–6 and 9–12 mg/d), and bipolar depression (3 studies; 6-to 8-week duration; cariprazine 1.5 and 3 mg/d). Long-term effects were analyzed using open-label studies in patients with schizophrenia (2 studies; 48-week duration) and patients with bipolar mania (1 study; 16-week duration). Change in prolactin levels (ng/mL) from baseline to study endpoint was evaluated in subsets of sex and prior medication use. Results: In patients with schizophrenia (male, n = 1377; female, n = 558), median prolactin changes were −1.2 for males and −7.4 for females on placebo, and ranged from −4.2 to −3.6 for males and −12.4 to +0.2 for females in the cariprazine-treatment groups. In patients with bipolar mania (male, n = 570; female, n = 395), median prolactin changes were −0.2 for males and −1.1 for females on placebo and ranged from −2.1 to −3.0 for males and 0 to +1.8 for females in the cariprazine-treatment groups. Median decreases were also seen in the long-term studies of schizophrenia (range, −14.6 to −2.0) and bipolar mania (range, −0.8 to +1.9). In patients with bipolar depression (male, n = 485; female, n = 780), median prolactin changes were +0.3 for males and +0.7 for females on placebo and ranged from +0.4 to +0.5 for males and +3.0 to +3.1 for females in the cariprazine-treatment groups. Conclusion: Treatment with cariprazine for schizophrenia or bipolar I disorder was associated with minimal effects on prolactin levels.

Cite

CITATION STYLE

APA

Culpepper, L., Vieta, E., Kelly, D. L., Patel, M. D., Szatmári, B., Hankinson, A., & Earley, W. R. (2022). Minimal Effects of Cariprazine on Prolactin Levels in Bipolar Disorder and Schizophrenia. Neuropsychiatric Disease and Treatment, 18, 995–1011. https://doi.org/10.2147/NDT.S348143

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free